Abstract
We evaluated the associations between baseline influenza virus–specific hemagglutination inhibition (HAI) and microneutralization (MN) titers and subsequent symptomatic influenza virus infection in a controlled human infection study. We inoculated unvaccinated healthy adults aged 18–49 years with an influenza A/California/04/2009/H1N1pdm-like virus (NCT04044352). We collected serial safety labs, serum for HAI and MN, and nasopharyngeal swabs for reverse-transcription polymerase chain reaction (RT-PCR) testing. Analyses used the putative seroprotective titer of ≥40 for HAI and MN. The primary clinical outcome was mild-to-moderate influenza disease (MMID), defined as ≥1 postchallenge positive qualitative RT-PCR test with a qualifying symptom/clinical finding. Of 76 participants given influenza virus challenge, 54 (71.1%) experienced MMID. Clinical illness was generally very mild. MMID attack rates among participants with baseline titers ≥40 by HAI and MN were 64.9% and 67.9%, respectively, while MMID attack rates among participants with baseline titers P = .126) for every 2-fold increase in baseline HAI. There were no significant adverse events. We achieved a 71.1% attack rate of MMID. High baseline HAI and MN were associated with protection from illness. Clinical Trials Registration. NCT04044352.
All Related Versions
Funding Information
  • NIAID
  • National Institutes of Health
  • (NIH) (HHSN272201300016I)
  • Cincinnati Children's Hospital Medical Center (75N93021C00012)
  • The Emmes Company (HHSN272201300022I)
  • University of Maryland (HHSN2722013000017I)
  • Duke University (HHSN272201300018I)
  • Emory University (HHSN272200800003C)
  • Saint Louis University (HHSN272201300015I)
  • Baylor College of Medicine
  • Institute for Clinical and Translational Research
  • at the
  • Baltimore
  • National Center for Advancing Translational Sciences
  • Clinical Translational Science Award (1UL1TR003098))

This publication has 33 references indexed in Scilit: